
Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.
View slated expert interviews and 5 clinical trials to watch at AASLD The Liver Meeting 2025.
The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025 kicks off in Washington, DC, on Friday, November 7, 2025. The 5-day conference boasts the latest research shaping the future of hepatology, including groundbreaking studies, clinical insights, and innovations from investigators around the world.






